Fig. 7: Treatment of FGFR1-altered gliomas with chemotherapy or targeted inhibitors show similar response rates. | Nature Communications

Fig. 7: Treatment of FGFR1-altered gliomas with chemotherapy or targeted inhibitors show similar response rates.

From: A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas

Fig. 7

a Pie chart showing the number of patients with FGFR-altered gliomas within the DFCI cohort that did (n = 6) or did not require further treatment (n = 9) following surgical management and had gross (n = 9) or sub-total (n = 6) resections (n = 15 patients total). b Bar graph depicts the % of FGFR1-altered pediatric glioma patients treated with chemotherapy (n = 6) or targeted inhibitors with either FGFR- or MEK-inhibition, broken down by low-grade (pLGG) or high-grade (pHGG) histology (pLGG: MEKi n = 8, FGFRi n = 24; pHGG: FGFRi n = 11). Chemotherapy-treated patients were from the DFCI cohort, targeted inhibitor-treated patients were from the DFCI cohort, published literature, and multi-institutional case studies. SD stable disease, PR partial response, PD progressive disease, CR complete response. Source data provided in Supplementary Data S7.

Back to article page